Novel insights of anti-EGFR therapy in HNSCC: combined with immunotherapy or not?
L Dong, Y Wang, X Yao, Y Ren, X Zhou - Current Oncology Reports, 2023 - Springer
Abstract Purpose of Review The efficacy of anti-EGFR therapy is still unfavorable in
recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) patients …
recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) patients …
Head and neck cancer: The role of anti-EGFR agents in the era of immunotherapy
M Fasano, CM Della Corte, G Viscardi… - … in medical oncology, 2021 - journals.sagepub.com
Head and neck cancers (HNC) represent the seventh most frequent cancer worldwide, with
squamous cell carcinomas as the most frequent histologic subtype. Standard treatment for …
squamous cell carcinomas as the most frequent histologic subtype. Standard treatment for …
Anti-EGFR targeted monoclonal antibody isotype influences antitumor cellular immunity in head and neck cancer patients
Purpose: EGF receptor (EGFR) is highly overexpressed on several cancers and two targeted
anti-EGFR antibodies which differ by isotype are FDA-approved for clinical use. Cetuximab …
anti-EGFR antibodies which differ by isotype are FDA-approved for clinical use. Cetuximab …
Current state and future directions of EGFR-directed therapy in head and neck cancer
P Tathineni, N Joshi, MJ Jelinek - Current Treatment Options in Oncology, 2023 - Springer
Opinion Statement Epidermal growth factor receptor (EGFR) is commonly overexpressed in
many head and neck squamous cell carcinomas (HNSCC). With the success of EGFR …
many head and neck squamous cell carcinomas (HNSCC). With the success of EGFR …
Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) have a high incidence and mortality
rate, and investigating the pathogenesis and potential therapeutic strategies of HNSCC is …
rate, and investigating the pathogenesis and potential therapeutic strategies of HNSCC is …
Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer
Head and neck squamous cell carcinoma (HNSCC) is an immunosuppressive malignancy.
Interest in developing novel immunotherapies in HNSCC has been reawakened by the …
Interest in developing novel immunotherapies in HNSCC has been reawakened by the …
Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a first-line
therapy for rapidly killing tumors such as those associated with non–small cell lung cancer …
therapy for rapidly killing tumors such as those associated with non–small cell lung cancer …
Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): a phase II study with biomarker analysis
Purpose: EGFR pathway inhibition may promote anti–programmed cell death protein 1 (PD-
1) responses in preclinical models, but how EGFR inhibition affects tumor antigen …
1) responses in preclinical models, but how EGFR inhibition affects tumor antigen …
Translational insights and new therapeutic perspectives in head and neck tumors
Head and neck squamous cell carcinoma (HNSCC) is characterized by a high mortality rate
owing to very few available oncological treatments. For many years, a combination of …
owing to very few available oncological treatments. For many years, a combination of …
Immune modulation of head and neck squamous cell carcinoma and the tumor microenvironment by conventional therapeutics
Head and neck squamous cell carcinoma (HNSCC) accounts for more than 600,000 cases
and 380,000 deaths annually worldwide. Although human papillomavirus (HPV)–associated …
and 380,000 deaths annually worldwide. Although human papillomavirus (HPV)–associated …